BRANDY SANFORD: Open Payments
NPI 1114414158 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$199 in 11 payments from 8 companies in 2025. Trend: 2023 $127 · 2024 $190 · 2025 $199
Food & beverage: $199
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $40 |
| Novo Nordisk Inc | 2 | $33 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| SANOFI PASTEUR INC. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $16 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $14 |
Products named: QULIPTA, REXULTI, FLUZONE HIGH-DOSE, GEMTESA, Ozempic, Wegovy, MOUNJARO, AIRSUPRA.
Industry payments across NE — which companies pay providers there.
